In conclusion, our results demonstrate that FPR2 mediates sex-specific responses to diet-induced NAFLD/NASH, suggesting a novel therapeutic target for NAFLD/NASH. This evidence concerns the gene FPR2 and metabolic dysfunction-associated steatotic liver disease.